Its role Technology / equipment supplier
Thermo Fisher Scientific Inc. is a leading provider of scientific instrumentation, reagents, consumables, software, and services for research, analysis, diagnostics, and manufacturing. Headquartered in Waltham, Massachusetts, the company was formed in 2006 from the merger of Thermo Electron and Fisher Scientific.
It operates in four main segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Key offerings include analytical instruments for chemical and material analysis, laboratory chemicals and reagents (organic, inorganic, solvents, and life science variants via brands like Thermo Scientific Chemicals and Alfa Aesar), cell culture media, genomic tools, and biopharma contract development and manufacturing.
Serving pharmaceutical, biotech, healthcare, academic, and industrial sectors—including chemical analysis and production—the company supports applications in drug discovery, environmental testing, and materials science. Thermo Fisher employs about 125,000 people worldwide and reported 2025 revenue of $44.56 billion (NYSE: TMO).
chemXplore tracks 1 project involving Thermo Fisher, of which one is active.
1 more active project is in the record. See all 1 in chemXplore →
Yokohama technical center began cell therapy process development in July 2025 and has been awarded multiple exosome and T‑cell projects, including a program transferred from Milan.
Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.
Deal covers commercial manufacturing of multiple biopharmaceuticals using new Yokohama site; revenue expected at several tens of billions of yen; GMP services targeted for 2027.
active all projects
